Search
Lanicemine
go.drugbank.com/drugs/DB11889InvestigationalLanicemine has been used in trials studying the treatment and basic science of Depression, Major Depressive Disorder, and Treatment Resistant Major Depressive Disorder.
Categories: Receptors, N-Methyl-D-Aspartate, antagonists & inhibitorsAbemaciclib
go.drugbank.com/drugs/DB12001ApprovedInvestigationalAbemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA gr...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesMafosfamide
go.drugbank.com/drugs/DB12083InvestigationalMafosfamide has been used in trials studying the treatment of Lymphoma, Leukemia, Meningeal Neoplasm, and Brain and Central Nervous System Tumors.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsTetrahydropalmatine
go.drugbank.com/drugs/DB12093InvestigationalTetrahydropalmatine is under investigation in clinical trial NCT02118610 (Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesErdafitinib
go.drugbank.com/drugs/DB12147ApprovedInvestigationalIn early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or m...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesBrincidofovir
go.drugbank.com/drugs/DB12151ApprovedInvestigationalBrincidofovir is an oral antiviral drug used in the treatment of human smallpox infections. It is a lipid conjugate pro-drug of the acyclic nucleotide analogue cidofovir - this lipid conjugate improves drug delivery to the target cells a...
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2B6 InhibitorsDeutetrabenazine
go.drugbank.com/drugs/DB12161ApprovedInvestigationalDeutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a d...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesPSI-697
go.drugbank.com/drugs/DB12211InvestigationalPSI-697 has been used in trials studying the treatment of Scleritis.
Categories: P-SelectinBergapten
go.drugbank.com/drugs/DB12216InvestigationalBergapten is under investigation in clinical trial NCT00533195 (Comparison of UVA1 Phototherapy Versus Photochemotherapy for Patients With Severe Generalized Atopic Dermatitis).
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsTriclabendazole
go.drugbank.com/drugs/DB12245ApprovedInvestigationalTriclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 Substrates